{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:46:11Z","timestamp":1778737571416,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197706"],"award-info":[{"award-number":["R35CA197706"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Schnipke Family Endowment Fund to Support Clinical Trials and Cancer Research; the Robert and Martina Poe Small Cell Carcinoma Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Small cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52\/56) and 86% (48\/56) of SCLC patient samples, respectively. Similarly, <jats:italic>ROR1<\/jats:italic> and <jats:italic>BCL2<\/jats:italic> were shown by qRT-PCR to have elevated expression in 79% (22\/28) and 100% (28\/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500\u2009nM or less. Synergy as defined by a combination index of &lt;1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.<\/jats:p>","DOI":"10.1038\/s41419-021-03855-w","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T11:06:39Z","timestamp":1622804799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predicting ROR1\/BCL2 combination targeted therapy of small cell carcinoma of the lung"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-4688","authenticated-orcid":false,"given":"Walter Z.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Shilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-5523","authenticated-orcid":false,"given":"Mohammad","family":"Hojjat-Farsangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-1921","authenticated-orcid":false,"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"3855_CR1","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.21037\/jtd.2017.11.52","volume":"9","author":"C Dayen","year":"2017","unstructured":"Dayen, C. et al. New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases. J. Thorac. Dis. 9, 5101\u20135111 (2017).","journal-title":"J. Thorac. Dis."},{"key":"3855_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3855_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","volume":"5","author":"N Borcherding","year":"2014","unstructured":"Borcherding, N., Kusner, D., Liu, G.-H. & Zhang, W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5, 496\u2013502 (2014).","journal-title":"Protein Cell"},{"key":"3855_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","volume":"21","author":"T Yamaguchi","year":"2012","unstructured":"Yamaguchi, T. et al. NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21, 348\u2013361 (2012).","journal-title":"Cancer Cell"},{"key":"3855_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep36447","volume":"6","author":"Y-Z Zheng","year":"2016","unstructured":"Zheng, Y.-Z. et al. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Sci. Rep. 6, 36447 (2016).","journal-title":"Sci. Rep."},{"key":"3855_CR6","doi-asserted-by":"publisher","first-page":"10731","DOI":"10.1073\/pnas.1708264114","volume":"114","author":"LZ Rassenti","year":"2017","unstructured":"Rassenti, L. Z. et al. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 114, 10731\u201310736 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3855_CR7","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266\u201317271 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3855_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10060","volume":"7","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi, T. et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat. Commun. 7, 10060 (2016).","journal-title":"Nat. Commun."},{"key":"3855_CR9","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan, A. et al. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin. Cancer Res. 23, 3061\u20133071 (2017).","journal-title":"Clin. Cancer Res"},{"key":"3855_CR10","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","volume":"32","author":"M Hojjat-Farsangi","year":"2018","unstructured":"Hojjat-Farsangi, M. et al. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia 32, 2291\u20132295 (2018).","journal-title":"Leukemia"},{"key":"3855_CR11","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","volume":"116","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc. Natl Acad. Sci. USA 116, 1370\u20131377 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3855_CR12","doi-asserted-by":"publisher","first-page":"e0198038","DOI":"10.1371\/journal.pone.0198038","volume":"13","author":"AH Daneshmanesh","year":"2018","unstructured":"Daneshmanesh, A. H. et al. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE 13, e0198038 (2018).","journal-title":"PLoS ONE"},{"key":"3855_CR13","first-page":"122","volume":"3","author":"N Karachaliou","year":"2014","unstructured":"Karachaliou, N. et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Transl. Lung Cancer Res 3, 122\u2013130 (2014).","journal-title":"Transl. Lung Cancer Res"},{"key":"3855_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi, M. Y. et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 22, 951\u2013959.e953 (2018).","journal-title":"Cell Stem Cell"},{"key":"3855_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/cdd.2014.87","volume":"22","author":"Y Pekarsky","year":"2015","unstructured":"Pekarsky, Y. & Croce, C. M. Role of miR-15\/16 in CLL. Cell Death Differ. 22, 6\u201311 (2015).","journal-title":"Cell Death Differ."},{"key":"3855_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 70, 440 (2010).","journal-title":"Cancer Res."},{"key":"3855_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/1947601912440575","volume":"2","author":"RJ Tallarida","year":"2011","unstructured":"Tallarida, R. J. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003\u20131008 (2011).","journal-title":"Genes Cancer"},{"key":"3855_CR18","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163\u20133169 (2012).","journal-title":"Clin. Cancer Res."},{"key":"3855_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jtho.2018.10.162","volume":"14","author":"SL Sinicropi-Yao","year":"2019","unstructured":"Sinicropi-Yao, S. L. et al. Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in NSCLC. J. Thorac. Oncol. 14, 223\u2013236 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"3855_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/biomedicines8060170","volume":"8","author":"A Ghaderi","year":"2020","unstructured":"Ghaderi, A. et al. ROR1 Is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells. Biomedicines 8, 170 (2020).","journal-title":"Biomedicines"},{"key":"3855_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05626-2","volume":"9","author":"RR Arasada","year":"2018","unstructured":"Arasada, R. R. et al. Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat. Commun. 9, 3198 (2018).","journal-title":"Nat. Commun."},{"key":"3855_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 21, 1163\u20131171 (2015).","journal-title":"Nat. Med."},{"key":"3855_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"3855_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1186\/1471-2164-14-778","volume":"14","author":"T Hart","year":"2013","unstructured":"Hart, T., Komori, H. K., LaMere, S., Podshivalova, K. & Salomon, D. R. Finding the active genes in deep RNA-seq gene expression studies. BMC genomics 14, 778\u2013778 (2013).","journal-title":"BMC genomics"},{"key":"3855_CR25","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944\u201313949 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3855_CR26","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1158\/0008-5472.CAN-04-3703","volume":"64","author":"RD Ramirez","year":"2004","unstructured":"Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64, 9027 (2004).","journal-title":"Cancer Res."},{"key":"3855_CR27","doi-asserted-by":"publisher","first-page":"TPS79","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79","volume":"36","author":"JM Specht","year":"2018","unstructured":"Specht, J. M. et al. Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. J. Clin. Oncol. 36, TPS79\u2013TPS79 (2018).","journal-title":"J. Clin. Oncol."},{"key":"3855_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc1913","volume":"6","author":"K Imai","year":"2006","unstructured":"Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714\u2013727 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"3855_CR29","doi-asserted-by":"publisher","first-page":"e00178","DOI":"10.1002\/prp2.178","volume":"3","author":"S Ackler","year":"2015","unstructured":"Ackler, S. et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol. Res. Perspect. 3, e00178\u2013e00178 (2015).","journal-title":"Pharmacol. Res. Perspect."},{"key":"3855_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fphar.2019.00697","volume":"10","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials. Front. Pharmacol. 10, 697\u2013697 (2019).","journal-title":"Front. Pharmacol."},{"key":"3855_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts, A. W. et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134, 111\u2013122 (2019).","journal-title":"Blood"},{"key":"3855_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","volume":"24","author":"TL Lochmann","year":"2018","unstructured":"Lochmann, T. L. et al. Venetoclax is effective in small cell lung cancers with high BCL-2 expression. Clin. Cancer Res 24, 360\u2013369 (2018).","journal-title":"Clin. Cancer Res"},{"key":"3855_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","volume":"9","author":"SW Lok","year":"2019","unstructured":"Lok, S. W. et al. A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2\u2013positive metastatic breast cancer. Cancer Discov. 9, 354 (2019).","journal-title":"Cancer Discov."},{"key":"3855_CR34","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","volume":"22","author":"VD Gonzalez","year":"2018","unstructured":"Gonzalez, V. D. et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 22, 1875\u20131888 (2018).","journal-title":"Cell Rep."},{"key":"3855_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360\u2013364 (2017).","journal-title":"Nature"},{"key":"3855_CR36","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn, A. et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc. Natl Acad. Sci. USA 111, 14788\u201314793 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3855_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289\u2013297 (2019).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03855-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03855-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03855-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:13:37Z","timestamp":1669972417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03855-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["3855"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03855-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local IRB and The Ohio State University and followed the Declaration of Helsinki Ethical principle for Medical Research Involving Human Subjects. Written informed consent was obtained by all participants prior to inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Dr. Mellstedt reports grants from Kancera AB, personal fees from Kancera AB, outside the submitted work. Dr. Carbone reports personal fees from Abbvie, personal fees from Adaptimmune, personal fees from Agenus, personal fees from Amgen, personal fees from Ariad, personal fees from AstraZeneca, personal fees from Biocept, personal fees from Boehringer Ingelheim, grants and personal fees from Bristol Myers-Squibb, personal fees from Celgene, personal fees from Clovis, personal fees from Daiichi Sankyo Inc., personal fees from EMD Serono, personal fees from Foundation Medicine, personal fees from GenePlus, personal fees from Genentech\/Roche, personal fees from Glaxo Smith Kline, personal fees from Gloria Bioscience, personal fees from Gritstone, personal fees from Guardant Health, personal fees from Helsinn, personal fees from Humana, personal fees from Incyte, personal fees from Inivata, personal fees from Inovio, personal fees from Janssen, personal fees from Kyowa Kirin, personal fees from Loxo Oncology, personal fees from Merck, personal fees from MSD, personal fees from Nexus Oncology, personal fees from Novartis, personal fees from Palobiofarma, personal fees from Pfizer, personal fees from prIME Oncology, personal fees from Stemcentrx, personal fees from Takeda Oncology, personal fees from Teva, outside the submitted work. The remaining others declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"577"}}